Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor
Objectives: To develop and validate a prognostic nomogram based on baseline nutritional and inflammatory parameters for risk stratification in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) receiving chemotherapy combination programmed death-1 (PD-1) inhibitor. Methods: This retro...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/19/4262 |
| _version_ | 1797575373427310592 |
|---|---|
| author | Jia Guo Qi Yang Qi Jiang Li-Wen Gu Huan-Xin Lin Ling Guo |
| author_facet | Jia Guo Qi Yang Qi Jiang Li-Wen Gu Huan-Xin Lin Ling Guo |
| author_sort | Jia Guo |
| collection | DOAJ |
| description | Objectives: To develop and validate a prognostic nomogram based on baseline nutritional and inflammatory parameters for risk stratification in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) receiving chemotherapy combination programmed death-1 (PD-1) inhibitor. Methods: This retrospective study analyzed 131 patients with dmNPC (88 and 43 in the training and validation cohorts, respectively) between March 2017 and November 2020. All these patients received chemotherapy combined with PD-1 inhibitor treatment. We identified independent risk factors using univariate and multivariate Cox regression analyses and established a nomogram to predict the progression-free survival (PFS). The predictive accuracy of the nomogram was evaluated and independently validated. Results: Baseline nutritional risk index (NRI), prognostic nutritional index (PNI), systemic immune-inflammation index (SII), uric acid (UA), and post-treatment Epstein–Barr virus (EBV) DNA were used to develop a nomogram that could divide patients into favorable- and unfavorable-prognosis groups. The median PFS (mPFS) was significantly longer in the favorable-prognosis group compared to the unfavorable-prognosis group (35.10 months [95% CI: 27.36–42.84] vs. 7.23 months [95% CI: 6.50–7.97]; <i>p</i> = 0.001). All results were confirmed in the validation cohort. Conclusions: The proposed model improved the prognostic risk stratification for patients with dmNPC undergoing chemotherapy combined with PD-1 inhibitor treatment. |
| first_indexed | 2024-03-10T21:37:40Z |
| format | Article |
| id | doaj.art-5e42eb09b0084cee93f79f1007aa8957 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-10T21:37:40Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-5e42eb09b0084cee93f79f1007aa89572023-11-19T14:52:27ZengMDPI AGNutrients2072-66432023-10-011519426210.3390/nu15194262Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 InhibitorJia Guo0Qi Yang1Qi Jiang2Li-Wen Gu3Huan-Xin Lin4Ling Guo5State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, ChinaObjectives: To develop and validate a prognostic nomogram based on baseline nutritional and inflammatory parameters for risk stratification in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) receiving chemotherapy combination programmed death-1 (PD-1) inhibitor. Methods: This retrospective study analyzed 131 patients with dmNPC (88 and 43 in the training and validation cohorts, respectively) between March 2017 and November 2020. All these patients received chemotherapy combined with PD-1 inhibitor treatment. We identified independent risk factors using univariate and multivariate Cox regression analyses and established a nomogram to predict the progression-free survival (PFS). The predictive accuracy of the nomogram was evaluated and independently validated. Results: Baseline nutritional risk index (NRI), prognostic nutritional index (PNI), systemic immune-inflammation index (SII), uric acid (UA), and post-treatment Epstein–Barr virus (EBV) DNA were used to develop a nomogram that could divide patients into favorable- and unfavorable-prognosis groups. The median PFS (mPFS) was significantly longer in the favorable-prognosis group compared to the unfavorable-prognosis group (35.10 months [95% CI: 27.36–42.84] vs. 7.23 months [95% CI: 6.50–7.97]; <i>p</i> = 0.001). All results were confirmed in the validation cohort. Conclusions: The proposed model improved the prognostic risk stratification for patients with dmNPC undergoing chemotherapy combined with PD-1 inhibitor treatment.https://www.mdpi.com/2072-6643/15/19/4262nasopharyngeal carcinomanutritional statusinflammationPD-1 inhibitorprognostic model |
| spellingShingle | Jia Guo Qi Yang Qi Jiang Li-Wen Gu Huan-Xin Lin Ling Guo Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor Nutrients nasopharyngeal carcinoma nutritional status inflammation PD-1 inhibitor prognostic model |
| title | Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor |
| title_full | Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor |
| title_fullStr | Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor |
| title_full_unstemmed | Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor |
| title_short | Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor |
| title_sort | integrating baseline nutritional and inflammatory parameters with post treatment ebv dna level to predict outcomes of patients with de novo metastatic nasopharyngeal carcinoma receiving chemotherapy combination pd 1 inhibitor |
| topic | nasopharyngeal carcinoma nutritional status inflammation PD-1 inhibitor prognostic model |
| url | https://www.mdpi.com/2072-6643/15/19/4262 |
| work_keys_str_mv | AT jiaguo integratingbaselinenutritionalandinflammatoryparameterswithposttreatmentebvdnaleveltopredictoutcomesofpatientswithdenovometastaticnasopharyngealcarcinomareceivingchemotherapycombinationpd1inhibitor AT qiyang integratingbaselinenutritionalandinflammatoryparameterswithposttreatmentebvdnaleveltopredictoutcomesofpatientswithdenovometastaticnasopharyngealcarcinomareceivingchemotherapycombinationpd1inhibitor AT qijiang integratingbaselinenutritionalandinflammatoryparameterswithposttreatmentebvdnaleveltopredictoutcomesofpatientswithdenovometastaticnasopharyngealcarcinomareceivingchemotherapycombinationpd1inhibitor AT liwengu integratingbaselinenutritionalandinflammatoryparameterswithposttreatmentebvdnaleveltopredictoutcomesofpatientswithdenovometastaticnasopharyngealcarcinomareceivingchemotherapycombinationpd1inhibitor AT huanxinlin integratingbaselinenutritionalandinflammatoryparameterswithposttreatmentebvdnaleveltopredictoutcomesofpatientswithdenovometastaticnasopharyngealcarcinomareceivingchemotherapycombinationpd1inhibitor AT lingguo integratingbaselinenutritionalandinflammatoryparameterswithposttreatmentebvdnaleveltopredictoutcomesofpatientswithdenovometastaticnasopharyngealcarcinomareceivingchemotherapycombinationpd1inhibitor |